TP53 and neuroendocrine carcinoma: In 2024, Kasajima et al.13identified acquired TP53 mutations and NEC‐like histological features (e.g., high‐grade atypia, diffuse growth patterns, and necrosis) in a subset of metastatic G3–Gastroenteropancreatic NETs associated with rapid tumour progression.